{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:11:18Z","timestamp":1790946678438,"version":"4.1.0"},"reference-count":126,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20441"],"award-info":[{"award-number":["20441"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation in the pathogenesis of multiple myeloma (MM), and discuss the potential use of miRs\/nanocarriers association in clinic. Since miRs can act as oncogenes or tumor suppressors, strategies based on their inhibition and\/or replacement represent the new opportunities in cancer therapy. The miRs delivery systems include liposomes, polymers, and exosomes that increase their physical stability and prevent nuclease degradation. Phase I\/II clinical trials support the importance of miRs as an innovative therapeutic approach in nanomedicine to prevent cancer progression and drug resistance. Results in clinical practice are promising.<\/jats:p>","DOI":"10.3390\/ijms21093084","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T05:05:32Z","timestamp":1588050332000},"page":"3084","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-2601","authenticated-orcid":false,"given":"Vanessa","family":"Desantis","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Saltarella","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Lamanuzzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Melaccio","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9698","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Solimando","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"},{"name":"Experimental Medical Oncology, IRCS Istituto Tumori \"Giovanni Paolo II\" of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Addolorata","family":"Mariggi\u00f2","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of General Pathology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8639-1940","authenticated-orcid":false,"given":"Vito","family":"Racanelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6495-2295","authenticated-orcid":false,"given":"Angelo","family":"Paradiso","sequence":"additional","affiliation":[{"name":"Experimental Medical Oncology, IRCS Istituto Tumori \"Giovanni Paolo II\" of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-8216","authenticated-orcid":false,"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Frassanito","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Unit of General Pathology, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: Emerging new players","volume":"7","author":"Desantis","year":"2016","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Da Vi\u00e0, M.C., Cicco, S., Leone, P., Di Lernia, G., Giannico, D., Desantis, V., Frassanito, M.A., Morizio, A., and Delgado Tascon, J. (2019). High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J. Clin. Med., 8.","DOI":"10.20944\/preprints201906.0145.v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: Small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: Genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2014.09.006","article-title":"miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies","volume":"81","author":"Chitkara","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cncr.26297","article-title":"Deregulated microRNAs in multiple myeloma","volume":"118","author":"Benetatos","year":"2012","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2174\/156800912802429355","article-title":"Promises and challenges of MicroRNA-based treatment of multiple myeloma","volume":"12","author":"Tagliaferri","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Handa, H., Murakami, Y., Ishihara, R., Kimura-Masuda, K., and Masuda, Y. (2019). The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma. Cancers, 11.","DOI":"10.3390\/cancers11111738"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"Micro RNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","article-title":"OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer","volume":"76","author":"Svoronos","year":"2016","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jconrel.2013.09.015","article-title":"Progress in microRNA delivery","volume":"172","author":"Zhang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000302889","article-title":"MicroRNA profiles of drug-resistant myeloma cell lines","volume":"123","author":"Munker","year":"2010","journal-title":"Acta Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2015-0003","article-title":"Nanocarrier-based co-delivery of small molecules and siRNA\/miRNA for treatment of cancer","volume":"7","author":"Chitkara","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104837","DOI":"10.1016\/j.chemphyslip.2019.104837","article-title":"Lipid nanocarriers for microRNA delivery","volume":"226","author":"Scheideler","year":"2020","journal-title":"Chem. Phys. Lipids"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/neuonc\/nou084","article-title":"MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras","volume":"16","author":"Shi","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/mp3002039","article-title":"Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy","volume":"9","author":"Qian","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","article-title":"Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances","volume":"194","author":"Gandhi","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","article-title":"MicroRNA maturation: Stepwise processing and subcellular localization","volume":"21","author":"Lee","year":"2002","journal-title":"EMBO J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ygeno.2020.01.005","article-title":"Identification and evolutionary analysis of polycistronic miRNA clusters in domesticated and wild wheat","volume":"112","author":"Singh","year":"2020","journal-title":"Genomics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1261\/rna.1731910","article-title":"Structure and activity of putative intronic miRNA promoters","volume":"16","author":"Monteys","year":"2010","journal-title":"RNA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The widespread regulation of microRNA biogenesis, function and decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1515\/hsz-2017-0329","article-title":"The AGO proteins: An overview","volume":"399","author":"Niaz","year":"2018","journal-title":"Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation","volume":"9","author":"Hayder","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nsmb.2296","article-title":"The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC","volume":"19","author":"Fabian","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/cdd.2014.112","article-title":"The complexity of miRNA-mediated repression","volume":"22","author":"Wilczynska","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2174\/156800912802429274","article-title":"MicroRNAs in the pathobiology of multiple myeloma","volume":"12","author":"Lionetti","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1093\/nar\/gkx327","article-title":"Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell","volume":"45","author":"Kassambara","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"35","author":"Pichiorri","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","article-title":"miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood-2007-03-081133","article-title":"Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer","volume":"110","author":"Loffler","year":"2007","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth","volume":"19","author":"Leone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2008.02.013","article-title":"E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer","volume":"13","author":"Petrocca","year":"2008","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.05.017","article-title":"miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma","volume":"309","author":"Chen","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/carcin\/bgq033","article-title":"Epigenetic inactivation of the miR-34a in hematological malignancies","volume":"31","author":"Chim","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: A new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Di Martino, M.T., Campani, V., Misso, G., Gallo Cantafio, M.E., Gull\u00e0, A., Foresta, U., Guzzi, P.H., Castellano, M., Grimaldi, A., and Gigantino, V. (2014). In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090005"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/1535-7163.MCT-15-0985","article-title":"Therapeutic Targeting of miR-29b\/HDAC4 Epigenetic Loop in Multiple Myeloma","volume":"15","author":"Amodio","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.18632\/oncotarget.675","article-title":"DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma","volume":"3","author":"Amodio","year":"2012","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbrc.2011.09.063","article-title":"Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1","volume":"414","author":"Zhang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1038\/cddis.2012.175","article-title":"miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1","volume":"3","author":"Amodio","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1182\/blood-2009-08-237495","article-title":"Identification of microRNA expression patterns and definition of a microRNA\/mRNA regulatory network in distinct molecular groups of multiple myeloma","volume":"114","author":"Lionetti","year":"2009","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/jcp.24669","article-title":"A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells","volume":"229","author":"Leotta","year":"2014","journal-title":"J. Cell Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/leu.2015.124","article-title":"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo","volume":"29","author":"Morelli","year":"2015","journal-title":"Leukemia"},{"key":"ref_48","first-page":"4001","article-title":"The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma","volume":"16","author":"Jiang","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10142-016-0519-7","article-title":"Integrative analysis of signaling pathways and diseases associated with the miR-106b\/25 cluster and their function study in berberine-induced multiple myeloma cells","volume":"17","author":"Gu","year":"2017","journal-title":"Funct. Integr. Genom."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e12081","DOI":"10.1097\/MD.0000000000012081","article-title":"The expression and role of miR-181a in multiple myeloma","volume":"97","author":"Yuan","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes","volume":"247","author":"Frassanito","year":"2019","journal-title":"J. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2013.12.043","article-title":"Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer","volume":"156","author":"Mori","year":"2014","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/jcp.24306","article-title":"miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease","volume":"228","author":"Rossi","year":"2013","journal-title":"J. Cell Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/leu.2017.336","article-title":"MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells","volume":"32","author":"Botta","year":"2018","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/bloodadvances.2019000403","article-title":"Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion","volume":"3","author":"Umezu","year":"2019","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1538-7445.NONRNA15-A17","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: Challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.apsb.2015.03.001","article-title":"Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment","volume":"5","author":"Kang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-60761-863-8_15","article-title":"The guideline of the design and validation of MiRNA mimics","volume":"676","author":"Wang","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/jcp.26514","article-title":"Treating cancer with microRNA replacement therapy: A literature review","volume":"233","author":"Hosseinahli","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/gt.2011.79","article-title":"Developing therapeutic microRNAs for cancer","volume":"18","author":"Bader","year":"2011","journal-title":"Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jconrel.2013.09.027","article-title":"Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/mp2002076","article-title":"MicroRNA delivery by cationic lipoplexes for lung cancer therapy","volume":"8","author":"Wu","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/mtna.2013.14","article-title":"Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer","volume":"2","author":"Wu","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_68","first-page":"4481","article-title":"Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2014.09.005","article-title":"Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression","volume":"194","author":"Shi","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12272-014-0451-0","article-title":"Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery","volume":"38","author":"Jung","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1158\/0008-5472.CAN-10-4645","article-title":"MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma","volume":"71","author":"Ibrahim","year":"2011","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7971","DOI":"10.1166\/jnn.2015.11233","article-title":"Simultaneous Drug and Gene Delivery from the Biodegradable Poly(\u03b5-caprolactone) Nanofibers for the Treatment of Liver Cancer","volume":"15","author":"Che","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jconrel.2015.02.018","article-title":"Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer","volume":"203","author":"Wang","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E1695","DOI":"10.1073\/pnas.1201516109","article-title":"Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma","volume":"109","author":"Babar","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1038\/srep17579","article-title":"Delivery of miR-34a by chitosan\/PLGA nanoplexes for the anticancer treatment of multiple myeloma","volume":"5","author":"Cosco","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"30876","DOI":"10.18632\/oncotarget.9021","article-title":"Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2013.02.019","article-title":"Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth","volume":"335","author":"Katakowski","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2015.11.056","article-title":"Effect of surface properties on liposomal siRNA delivery","volume":"79","author":"Xia","year":"2016","journal-title":"Biomaterials"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/sj.cgt.7700218","article-title":"Cationic lipid-based delivery system for systemic cancer gene therapy","volume":"7","author":"Anwer","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/17425247.2013.798640","article-title":"Nanoparticle-mediated delivery of therapeutic genes: Focus on miRNA therapeutics","volume":"10","author":"Muthiah","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/10430340360535751","article-title":"Stability of mRNA\/cationic lipid lipoplexes in human and rat cerebrospinal fluid: Methods and evidence for nonviral mRNA gene delivery to the central nervous system","volume":"143","author":"Anderson","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1038\/sj.onc.1210293","article-title":"MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells","volume":"26","author":"Welch","year":"2007","journal-title":"Oncogene"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3892\/ol.2015.3649","article-title":"MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13375","article-title":"miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2","volume":"512","author":"Krzeszinski","year":"2014","journal-title":"Nature"},{"key":"ref_88","first-page":"1212","article-title":"Novel cationic polymers and glycodendrimers for gene delivery","volume":"227","author":"Srinivasachari","year":"2004","journal-title":"Pap. Am. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1023\/A:1011981000671","article-title":"Chitosan-based vector\/DNA complexes for gene delivery: Biophysical characteristics and transfection ability","volume":"15","author":"Erbacher","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BA20060163","article-title":"A novel PEGylation of chitosan nanoparticles for gene delivery","volume":"46","author":"Zhang","year":"2007","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.biotechadv.2017.03.002","article-title":"Nanocarriers for microRNA delivery in cancer medicine","volume":"35","author":"Badiola","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1096\/fj.13-238527","article-title":"Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation","volume":"28","author":"Devalliere","year":"2014","journal-title":"FASEB J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"C621","DOI":"10.1152\/ajpcell.00228.2013","article-title":"Extracellular membrane vesicles as a mechanism of cell-to-cell communication: Advantages and disadvantages","volume":"306","author":"Turturici","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"188340","DOI":"10.1016\/j.bbcan.2020.188340","article-title":"Communication in tiny packages: Exosomes as means of tumor-stroma communication","volume":"1873","author":"Egeblad","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/leu.2017.248","article-title":"Response commentary: Exosomes vs microvesicles in hematological malignancies","volume":"31","author":"Whiteside","year":"2017","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/wrna.115","article-title":"Horizontal transfer of RNAs: Exosomes as mediators of intercellular communication","volume":"3","author":"Ramachandran","year":"2012","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.celrep.2014.07.035","article-title":"Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells","volume":"8","author":"Squadrito","year":"2014","journal-title":"Cell Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/leu.2016.296","article-title":"The LIN28B\/let-7 axis is a novel therapeutic pathway in multiple myeloma","volume":"31","author":"Manier","year":"2017","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.cell.2009.04.040","article-title":"SnapShot: MicroRNAs in Cancer","volume":"137","author":"Spizzo","year":"2009","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.molmed.2008.07.001","article-title":"let-7 microRNAs in development, stem cells and cancer","volume":"14","author":"Slack","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"R78","DOI":"10.1186\/bcr3693","article-title":"MicroRNA-18a inhibits hypoxia-inducible factor 1\u03b1 activity and lung metastasis in basal breast cancers","volume":"16","author":"Krutilina","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S1321","DOI":"10.21037\/tcr.2017.09.29","article-title":"Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy","volume":"6","author":"Baldari","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/onc.2011.381","article-title":"MicroRNA miR-146b-5p regulates signal transduction of TGF-\u03b2 by repressing SMAD4 in thyroid cancer","volume":"31","author":"Geraldo","year":"2012","journal-title":"Oncogene"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1479-5876-3-10","article-title":"Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst phase I clinical trial","volume":"3","author":"Escudier","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/mt.2008.1","article-title":"Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer","volume":"16","author":"Dai","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-5876-3-9","article-title":"A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer","volume":"3","author":"Morse","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fgene.2019.00478","article-title":"The Potential for microRNA Therapeutics and Clinical Research","volume":"10","author":"Hanna","year":"2019","journal-title":"Front. Genet."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2016.34.15_suppl.2508","article-title":"MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: Final dose-escalation results from a first-in-human phase I trial of microRNA therapy","volume":"34","author":"Hong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Invest New Drugs"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Hong, D.S., Kang, Y.K., Borad, M., Sachdev, J., Ejadi, S., Lim, H.Y., Brenner, A.J., Park, K., Lee, J.L., and Kim, T.Y. (2020). Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer.","DOI":"10.1038\/s41416-020-0802-1"},{"key":"ref_111","first-page":"303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_112","first-page":"5153","article-title":"MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3\/JAK-STAT3 signaling pathway","volume":"21","author":"Li","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_113","first-page":"4253","article-title":"MicroRNA-92 regulates vascular smooth muscle cell function by targeting KLF4 during vascular restenosis and injury","volume":"12","author":"Deng","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_114","first-page":"14","article-title":"MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT","volume":"23","author":"Zhen","year":"2016","journal-title":"J. Biol. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40169-018-0211-8","article-title":"Combination therapy to checkmate Glioblastoma: Clinical challenges and advances","volume":"7","author":"Ghosh","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/tlcr.2018.01.11","article-title":"Response to \u201cAn innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)\u201d","volume":"7","author":"McDiarmid","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"ref_118","first-page":"6094","article-title":"The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma","volume":"15","author":"Zhu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"17949","DOI":"10.1038\/s41598-017-18186-0","article-title":"Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment","volume":"7","author":"Zarone","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","article-title":"Targeting the miR-221-222\/PUMA\/BAK\/BAX pathway abrogates dexamethasone resistance in multiple myeloma","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells","volume":"22","author":"Morelli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/leu.2014.279","article-title":"MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib","volume":"29","author":"Jagannathan","year":"2015","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3109\/10428194.2011.591004","article-title":"Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation","volume":"52","author":"Wang","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/leu.2013.262","article-title":"MicroRNA theragnostics for the clinical management of multiple myeloma","volume":"28","author":"Ahmad","year":"2014","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2014.5","article-title":"Multifunctional aptamer-miRNA conjugates for targeted cancer therapy","volume":"22","author":"Esposito","year":"2014","journal-title":"Mol Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2016.10.014","article-title":"miRNA nanotherapeutics for cancer","volume":"22","author":"Ganju","year":"2017","journal-title":"Drug Discov. Today"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3084\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:17Z","timestamp":1760364557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":126,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093084"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093084","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]}}}